Zomedica Corp. — fact timeline

Zomedica Corp. shareholders approved Amendment to the By-Laws of the Company to address the quorum requirements for an adjourned meeting of Shareholders at the 2026-06-10 meeting.

“Proposal 4 ; Amendment of the Company’s By-Laws The votes cast to approve an amendment to the By-Laws of the Company to address the quorum requirements for an adjourned meeting of Shareholders as described in the our management information circular and proxy statement for the Annual Meeting were as follows: . For: 123,410,315 Against: 105,771,772 Broker Non-Vote 200,401,613”

Zomedica Corp. shareholders rejected Advisory vote to approve the compensation of our named executive officers as described in our management information circular and proxy statement for the Annual Meeting at the 2026-06-10 meeting.

“Proposal 3: Advisory Vote on the Company’s Executive Compensation The votes cast on the advisory vote to approve the compensation of our named executive officers disclosed in our management information circular and proxy statement for the Annual Meeting were as follows: For: 99,891,977 Against: 129,290,109 Broker Non-Vote 200,401,613”

Zomedica Corp. shareholders approved Ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for 2026 at the 2026-06-10 meeting.

“Proposal 2: Ratification of Independent Auditors For: 403,285,558 Withheld: 26,298,141”

Zomedica Corp. shareholders approved Election of eight directors, each for a one-year term at the 2026-06-10 meeting.

“Proposal 1: Election of Eight Directors For Withheld Broker Non-Vote Jeffrey Rowe 148,970,700 80,211,388 200,401,611 Robert Cohen 141,153,095 88,028,993 200,401,611 Chris Macleod 141,041,101 88,140,987 200,401,611 Pam Nichols 146,791,443 82,390,645 200,401,611 Johnny D. Powers 151,457,102 77,724,986 200,401,611 Sean Whelan 141,437,085 87,745,003 200,401,611 Rodney Williams 141,615,934 87,566,154 200,401,611 Larry Heaton 148,997,578 80,184,510 200,401,611”

Zomedica Corp. reported the first quarter ended March 31, 2026 results: revenue $8.8 million.

“Zomedica Announces Record First Quarter Revenue of $8.8 Million”

Zomedica Corp. reported the year ended December 31, 2025 results: revenue $32.0 million, net income $81.9 million.

“(PRESS RELEASE) --- EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity Zomedica surpasses $10 million in quarterly revenue for the first time”

Zomedica Corp. reported the fourth quarter ended December 31, 2025 results: revenue $10.5 million.

“Revenue for the fourth quarter of 2025 grew 33% to $10.5 million”

Michael Zuehlke was appointed as Vice President of Finance and Corporate Controller at Zomedica Corp..

“Until a Chief Financial Officer is hired to replace Mr. Jordan, Mr. Michael Zuehlke, Vice President of Finance and Corporate Controller of Zomedica Inc. will assume operational responsibility for accounting and finance matters.”

Scott Jordan resigned as Chief Financial Officer at Zomedica Corp..

“Effective April 25, 2025, Scott Jordan resigned from employment as Chief Financial Officer of Zomedica Corp.”

Zomedica Corp. received a nyse_american delisting notice notice regarding minimum bid price (rules 1003(f)(v)).

“March 4, 2025, Zomedica Corp. (the “ Company ”) was notified by The NYSE American LLC (“ NYSE American ”) that as a result of the Company’s previously disclosed noncompliance with Section 1003(f)(v) of the NYSE American Company Guide whereby the Company’s common shares were trading for a substantial period of time at a low price per share, NYSE American has suspended trading in the Company’s common shares as of March 4, 2025. NYSE American further indicated that it will apply to the Securities and Exchange Commission (the “ SEC ”) to delist the Company’s common shares upon completion of all ap”

Zomedica Corp. reported full year 2024 results: revenue $31 to $35 million. Guidance reaffirmed.

“For the full year 2024, the Company continues to expect full year revenue in the range of $31 to $35 million, an increase of approximately 39% at the high end of the range, over full year 2023 revenue of $25.2 million.”

Zomedica Corp. reported the quarter ended March 31, 2024 results: revenue $6.3 million, net income $9.2 million, EPS $0.01 per share.

“Revenue for the three months ended March 31, 2024, was $6.3 million, compared to $5.5 million for the three months ended March 31, 2023, an increase of $0.8 million or approximately 14%. The increase was driven by growth in both operating segments: Therapeutic Devices and Diagnostics. Cost of revenue was $2.1 million, compared to $1.6 million for the three months ended March 31, 2023, an increase of $0.5 million. Margins remained strong at 66%, in line with expectations. Adjusting for our Qorvo Biotechnologies LLC (“QBT”) acquisition and other one-time items brings our gross margin for the quarter to over 69%, in line with recent levels. Operating expenses were $14.5 million, compared to $11.3 million for the three months ended March 31, 2023, an increase of $3.2 million or 28%. When adjusted for one-time, non-recurring charges, and expenses associated with ongoing QBT operations, total operating expenses grew just over 20% on a comparative basis. We continue to expect total operating”

Zomedica Corp. reported full year 2024 results: revenue $31 to $35 million. Guidance reaffirmed.

“Zomedica continues to expect full year revenue in the range of $31 to $35 million”

Zomedica Corp. reported the year ended December 31, 2023 results: revenue $25.2 million.

“X-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp.”

Zomedica Corp. reported the fourth quarter ended December 31, 2023 results: revenue $7.3 million.

“Revenue for the fourth quarter of 2023 grew 19% to $7.3 million”

Zomedica Corp. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v)).

“March 13, 2024, Zomedica Corp. (the “Company”) announced that it was continuing its dialogue with the NYSE American LLC (the “NYSE American”) regarding next steps associated with the deficiency letter (the “Letter”) the Company received from NYSE American on September 12, 2023. As reported in a prior Form 8-K, the Letter indicated that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company’s common shares were trading for a substantial period of time at a l”

Zomedica Corp. shareholders rejected Approve an amendment to the Company's Articles of Incorporation to effect a share consolidation (reverse split) at a ratio of 80-for-1 at the 2024-02-28 meeting.

“Approve an amendment to the Company's Articles of Incorporation (“Articles”) to effect a share consolidation (reverse split) of our issued and outstanding Common Shares at a ratio of 80-for-1, the implementation and timing of which shall be subject to the discretion of our Board of Directors (the “Share Consolidation Proposal”). The final votes cast on the Share Consolidation Proposal were as follows: For: 136,067,529 39.44% Against: 206,789,223 59.95% Abstain: 2,109,080 0.61%”

Zomedica Corp. reported the quarter ended September 30, 2023 results: revenue $6.3 million.

“EX-99.1 (PRESS RELEASE) --- EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies ANN ARBOR, MI / ACCESSWIRE /”

Zomedica Corp. amended BAW Sensor Supply Agreement with QBT (effective 2023-10-04).

“(the “Seller”), pursuant to which ZomInc acquired 100% of the issued and outstanding membership interest of Qorvo Biotechnologies, LLC, a Delaware limited liability company (“QBT”) in exchange for the purchase price set forth in the Purchase Agreement. QBT develops the TRUFORMA® Platform that utilizes innovative Bulk Acoustic Wave sensor technology to provide a non-optical and fluorescence free system for the detection of disease at the point of care.”

Zomedica Corp. entered into Transition Services Agreement with QBT (effective 2023-10-04).

“(the “Seller”), pursuant to which ZomInc acquired 100% of the issued and outstanding membership interest of Qorvo Biotechnologies, LLC, a Delaware limited liability company (“QBT”) in exchange for the purchase price set forth in the Purchase Agreement. QBT develops the TRUFORMA® Platform that utilizes innovative Bulk Acoustic Wave sensor technology to provide a non-optical and fluorescence free system for the detection of disease at the point of care.”

Zomedica Corp. terminated Development and Manufacturing License Agreement with QBT (effective 2023-10-04).

“each of (i) the Transition and Support Agreement and (ii) the Development and Manufacturing License Agreement, in each case, entered into between QBT, the Company and ZomInc dated as of January 17, 2023 was automatically and immediately terminated”

Zomedica Corp. terminated Transition and Support Agreement with QBT (effective 2023-10-04).

“each of (i) the Transition and Support Agreement and (ii) the Development and Manufacturing License Agreement, in each case, entered into between QBT, the Company and ZomInc dated as of January 17, 2023 was automatically and immediately terminated”

Zomedica Corp. entered into Purchase Agreement with Qorvo US, Inc. (effective 2023-10-04).

“On October 4, 2023, Zomedica Inc. (“ZomInc”), a wholly owned subsidiary of Zomedica Corp. (the “Company”), entered into an LLC membership interest purchase agreement (the “Purchase Agreement”) with Qorvo US, Inc. (the “Seller”), pursuant to which ZomInc acquired 100% of the issued and outstanding membership interest of Qorvo Biotechnologies, LLC”

Zomedica Corp. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).

“September 12, 2023, Zomedica Corp. (the “Company”) received a deficiency letter (the “Letter”) from the NYSE American LLC (the “NYSE American”) indicating that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company’s common shares were selling for a substantial period of time at a low price per share, which the NYSE American determined to be a 30-trading day average of less than $0.20 per share. The Letter does not result in the immediate delisting of the C”

Zomedica Corp. completed an acquisition involving Structured Monitoring Products, Inc. for $12,656,676 (closed 2023-09-05).

“an implied value of $5,095,196 based upon the parties agreed enterprise value of SMP. Following working capital adjustments and deduction of transaction expenses, Zomedica paid $12,656,676 for the balance of the SMP equity. The cash purchase price was funded through a $250,000 deposit previously paid to SMP and $12,406,677 of cash on hand. The Acquisition was”

Zomedica Corp. entered into Stock Purchase Agreement with Structured Monitoring Products, Inc. and its shareholders valued at $18,000,000 (effective 2023-09-04).

“On September 4, 2023, Zomedica Inc., a wholly-owned subsidiary of Zomedica Corp. (the “Company”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) pursuant to which Zomedica Inc. acquired 100% of the capital stock of Structured Monitoring Products, Inc., a Florida corporation (“SMP”) from SMP’s shareholders (“Sellers”).”

Zomedica Corp. reported the quarter ended June 30, 2023 results: revenue $6.0 million.

“or incorporated by reference therein. --- EX-99.1 (EX-99.1) --- zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / August 10, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a”

Zomedica Corp. shareholders approved Advisory vote to approve compensation of named executive officers at the 2023-06-13 meeting.

“The votes cast on the advisory vote to approve the compensation of our named executive officers disclosed in our management information circular and proxy statement for the Annual Meeting were as follows: For: 72,557,673 Against: 20,608,605 Abstain: 3,181,226 Broker Non-Vote 198,462,604”

Zomedica Corp. shareholders approved Ratification of appointment of Grant Thornton LLP as independent registered public accounting firm for 2023 at the 2023-06-13 meeting.

“The votes cast on the ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for 2023 were as follows: For: 275,373,176 Withheld: 19,436,932 Total: 294,810,108”

Zomedica Corp. shareholders approved Election of eight directors for a one-year term at the 2023-06-13 meeting.

“The votes cast on the election of directors were as follows: For Withheld Broker Non-Vote Jeffrey Rowe 87,730,995 8,616,651 198,462,462 Robert Cohen 83,920,921 12,426,725 198,462,462 Chris Macleod 86,929,501 9,418,145 198,462,462 Pam Nichols 87,669,282 8,678,364 198,462,462 Johnny D. Powers 87,343,642 9,004,004 198,462,462 Sean Whelan 87,193,145 9,154,501 198,462,462 Rodney Williams 86,170,305 10,177,341 198,462,462 Larry Heaton 87,496,102 8,851,544 198,462,462”

Zomedica Corp. reported three months ended March 31, 2023 results: revenue $5.5 million.

“Revenue for the first quarter of 2023 was $5.5 million”

Zomedica Corp. amended Lease Amendment with ULF Northfield Business Center LLC (effective 2023-05-10).

“On May 10, 2023, Zomedica, Inc., a wholly-owned subsidiary of Zomedica Corp., entered into an amendment (the “Lease Amendment”) to the Multi-Tenant Industrial Triple Net Lease with an effective date of March 18, 2022 (the “Lease”) by and between ULF Northfield Business Center LLC (the “Landlord”) and Zomedica, Inc.”

Peter Donato was appointed as Chief Financial Officer at Zomedica Corp..

“Also on March 16, 2023, Peter Donato was appointed as the Company’s Chief Financial Officer, effective immediately.”

Ann Marie Cotter resigned as Chief Financial Officer at Zomedica Corp..

“On March 16, 2023, Ann Marie Cotter resigned from employment as Chief Financial Officer of Zomedica Corp.”

Zomedica Corp. reported fourth quarter and year ended 2022 results: revenue approximately $6.0-$6.2 million.

“Revenue for the fourth quarter of 2022 is expected to be approximately $6.0-$6.2 million”

Zomedica Corp. entered into Development and Manufacturing License Agreement with Qorvo Biotechnologies, LLC valued at One-time license fee of $4 million on effective date, additional $4 million upon installation qualif (effective 2023-01-17).

“The License Agreement grants ZomInc a license to use certain of Qorvo's product technology and intellectual property rights in connection with ZomInc's development, manufacture, offer and sale of TRUFORMA products throughout the world. The term of the License Agreement is perpetual unless earlier terminated by the parties. The license granted to ZomInc by Qorvo shall remain exclusive for ten years, however this exclusivity may be extended thereafter in return for a one-time extension fee of $8 million. ZomInc has agreed to pay Qorvo a one-time license fee of $4 million on the effective date of the License Agreement and another payment of $4 million upon ZomInc's completion of the installation qualification process contemplated by the Transition Agreement for a cartridge production line at any ZomInc facility, subject to a prorated refund provision in the event Qorvo ceases the manufacture of BAW Sensors during the initial ten-year exclusivity period.”

Zomedica Corp. entered into BAW Sensor Supply Agreement with Qorvo Biotechnologies, LLC valued at Fixed price for BAW sensors; exclusivity in veterinary medicine field (effective 2023-01-17).

“Under the Supply Agreement, Qorvo has agreed to supply ZomInc with BAW sensors for ZomInc's use in its TRUFORMA products. For the term of the Supply Agreement, or until the license granted under the License Agreement is no longer exclusive, Qorvo has agreed not to supply BAW Sensors to any other person or entity specializing in veterinary medicine to make or commercialize diagnostic instruments, assays or cartridges in the veterinary medicine field. 2 ZomInc will pay a fixed price for the BAW sensors and may solely use the BAW sensors in connection with developing, manufacturing and commercializing its TRUFORMA products and in accordance with the terms and conditions of the License Agreement.”

Zomedica Corp. entered into Transition and Support Agreement with Qorvo Biotechnologies, LLC valued at Service charges offset against prior deposit; minimum cartridge purchase commitments in 2023 and 202 (effective 2023-01-17).

“The Transition Agreement contemplates the transition of TRUFORMA cartridge and instrument manufacturing, along with TRUFORMA assay and software development, to ZomInc over a two-year transition period. The Transition Agreement calls for the establishment of a Joint Transition Committee staffed by representatives of Qorvo and ZomInc who will meet on a regular basis and be responsible for overseeing and coordinating the transition. ZomInc has agreed to pay service charges to Qorvo for its services provided under the Transition Agreement which payments will first be offset against a large deposit paid by ZomInc pursuant to a previous purchase order. In addition, ZomInc has agreed to purchase a minimum number of production cartridges and development cartridges from Qorvo in 2023 and 2024 at predetermined prices.”

Zomedica Corp. entered into Distribution Agreement with Structured Monitoring Products, Inc. valued at Company acquired non-exclusive rights to distribute VetGuardian remote animal vital sign and surveil (effective 2023-01-13).

“On January 13, 2023 (the “Effective Date”), the wholly-owned subsidiary of Zomedica Corp., Zomedica Inc. (the “Company”), entered into Distribution Agreement (the “Distribution Agreement”) with Structured Monitoring Products, Inc. (“SMP”) whereby the Company acquired non-exclusive rights to distribute the VetGuardian remote animal vital sign and surveillance monitoring device (the “Product”).”

Zomedica Corp. reported the three months ended September 30, 2022 results: revenue $4.78 million, net income $5.00 million, EPS $0.005 per share.

“Summary Third Quarter 2022 Results Zomedica reported a net loss for the three months ended September 30, 2022, of $5.00 million, or $0.005 per share, compared to a net loss of $6.35 million, or $0.006 per share, for the three months ended September 30, 2021, a decrease in losses of $1.35 million or approximately 21%. Zomedica reported a net loss for the nine months ended September 30, 2022, of $14.21 million, or $0.014 per share, compared to a net loss of $15.09 million, or $0.050 per share, after adjustments for equity charges, for the nine months ended September 30, 2021, a decrease in losses of $0.88 million or approximately 6%. Revenue for the three months ended September 30, 2022, was $4.78 million, compared to $0.02 million for the three months ended September 30, 2021, an increase of $4.76 million or approximately 23,800%.”

Dr. Pamela Nichols was appointed as Director at Zomedica Corp..

“On August 23, 2022 the Board of Directors (the “Board”) of Zomedica Corp. (the “Company”) increased the size of our Board from six to seven members and appointed Dr. Pamela Nichols, DVM to fill the newly created vacancy on the Board.”

Karen DeHaan-Fullerton was appointed as Chief Counsel and Corporate Secretary at Zomedica Corp..

“On June 13, 2022, the Company appointed Karen DeHaan-Fullerton as the Company’s Chief Counsel and Corporate Secretary.”

Anthony K. Blair was appointed as Chief Operating Officer at Zomedica Corp..

“On June 13, 2022, Zomedica Corp. (the “Company”) appointed Anthony K. Blair as the Company’s Chief Operating Officer, effective immediately.”

Bruk Herbst departed as Chief Commercial Officer at Zomedica Corp..

“On November 19, 2021, Bruk Herbst was separated from employment as Chief Commercial Officer of Zomedica Corp. (the “Company”).”

Robert Cohen retired as Chief Executive Officer at Zomedica Corp..

“Mr. Cohen’s previously announced retirement as Chief Executive Officer will be effective.”

Larry Heaton was appointed as Chief Executive Officer at Zomedica Corp..

“On November 1, 2021, Mr. Heaton will succeed Robert Cohen as the Chief Executive Officer of the Company”

Larry Heaton was appointed as President at Zomedica Corp..

“On October 1, 2021, the Board of Directors of Zomedica Corp. (the “Company”) appointed Larry Heaton as the Company’s President, effective immediately.”

Sean Whelan was appointed as member of the Board of Directors at Zomedica Corp..

“On September 13, 2021, the Board appointed Sean Whelan as a member of the Board to fill the vacancy created by Mr. Wolfenberg’s resignation.”

Christopher Wolfenberg resigned as member of the Board of Directors at Zomedica Corp..

“On September 13, 2021, Christopher Wolfenberg resigned, effective immediately, as a member of the Board of Directors (the “Board”) of Zomedica Corp. (the “Company”).”